A genetic counselor tells the Toronto Star that she's seen more and more individuals who don't know what to do with their consumer genetic testing results.
According to Wired, Nebula Genomics is providing a way for people to get their genomes sequenced anonymously.
A 26-year-old woman tells Cosmopolitan about learning her APOE status at a young age.
Former Orig3n employees raise concerns about its testing at Bloomberg Businessweek.
As part of the shift, DNA.Land, which was run as an academic research project, will delete all data by the end of the month and ask customers to resubmit it.
MyHeritage plans to offer Promethease free of charge through the end of this year and to maintain SNPedia as a free resource for academic and non-profit users.
MPR News reports on efforts to tighten protections for genetic testing customers.
During a conference call to discuss the firm's second-quarter results, CEO and President Francis deSouza also highlighted potential growth from clinical sequencing.
23andMe and GlaxoSmithKline's partnership has uncovered half a dozen drug targets but also raised ethical questions, the Wall Street Journal reports.
The Guardian reports that some UK physicians are calling for increased regulation of direct-to-consumer genetic tests.
Russian CRISPR researcher moves along with plans to ultimately alter the genes of embryos of deaf couples, though awaits regulatory approval, Nature News reports.
University of California, San Francisco, researchers have uncovered a gene mutations that appears to make a father-son duo more efficient sleepers.
NPR reports a large health insurer has begun to cover some pharmacogenetic tests for psychiatric drugs.
In PLOS this week: genome-wide association study of non-syndromic orofacial cleft subtypes, epigenetic and transcriptomic analysis of pancreatic ductal adenocarcinoma, and more.